Jump to Main Content
Novel monoclonal antibody against alphaX subunit from horse CD11c/CD18 integrin
- Espino-Solis, Gerardo Pavel, Quintero-Hernandez, Veronica, Olvera-Rodriguez, Alejandro, Calderon-Amador, Juana, Pedraza-Escalona, Martha, Licea-Navarro, Alexei, Flores-Romo, Leopoldo, Possani, Lourival Domingos
- Veterinary immunology and immunopathology 2015 v.164 no.3-4 pp. 220-226
- Escherichia coli, Western blotting, dendritic cells, enzyme-linked immunosorbent assay, epitopes, horses, immunohistochemistry, integrins, lymph nodes, mice, monoclonal antibodies, mononuclear leukocytes, vaccines
- The αX I-domain of the horse integrin CD11c was successfully expressed in Escherichia coli, purified, biochemically characterized and used as immunogen to generate murine monoclonal antibodies against horse CD11c, which are not yet commercially available. One monoclonal antibody mAb-1C4 against the αX I-domain, is an IgG2a able to interact with the recombinant I-domain, showing an EC50=2.4ng according to ELISA assays. By western blot with horse PBMCs lysates the mAb-1C4 recognized a protein of 150kDa which corresponds well with the CD11c molecule. Using immunohistochemistry in horse lymph node tissue sections, mAb-1C4 marked cells in situ, some with apparent dendritic morphology. Thus the mAb generated to a recombinant epitope from horse CD11c identified the molecule in intact cells within horse lymphoid tissue. By the labelling intensity, the histological location (paracortical and interfollicular areas) and the apparent morphology of the marked cells, we can say that these are putative horse dendritic cells (DCs). The development of a mAb to horse CD11c provides a new tool to better study the horse DC biology and opens other biotechnological avenues, such as DC targeting-based vaccines.